or Try an Advanced Search...

    Lestaurtinib Stocks List

    Symbol Grade Name % Change
    CRDF B Cardiff Oncology, Inc. -4.36
    View As Page of Charts
    Related Industries: Diagnostics & Research
    Related Stock Lists: Acute Myeloid Leukemia Adenosine Advanced Solid Tumors Antineoplastic Drugs Cancer Cancer Treatment Chemotherapy Clinical Medicine Colorectal Cancer Drugs Leukemia Lymphoma Medicine Metastatic Castration Resistant Prostate Cancer Metastatic Colorectal Cancer Nektar Therapeutics Oncology Pharmaceutical Phosphates Prostate Cancer

    Related ETFs - A few ETFs which own one or more of the above listed Lestaurtinib stocks.

    Symbol Grade Name Weight
    IWC C iShares Microcap ETF 0.06
    AVSC C Avantis U.S. Small Cap Equity ETF 0.01
    VXF C Vanguard Extended Market ETF 0.0
    View all Lestaurtinib ETFs...
    Compare ETFs
    Compare AVSC to VXF Compare IWC to AVSC Compare IWC to VXF

        Lestaurtinib Stocks Recent News

        Date Stock Title
        Related Industries: Diagnostics & Research
        Related Stock Lists: Acute Myeloid Leukemia Adenosine Advanced Solid Tumors Antineoplastic Drugs Cancer Cancer Treatment Chemotherapy Clinical Medicine Colorectal Cancer Drugs Leukemia Lymphoma Medicine Metastatic Castration Resistant Prostate Cancer Metastatic Colorectal Cancer Nektar Therapeutics Oncology Pharmaceutical Phosphates Prostate Cancer
        Lestaurtinib

        Lestaurtinib (rINN, codenamed CEP-701) is a tyrosine kinase inhibitor structurally related to staurosporine. This semisynthetic derivative of the indolocarbazole K252a was investigated by Cephalon as a treatment for various types of cancer. It is an inhibitor of the kinases fms-like tyrosine kinase 3 (FLT3), Janus kinase 2 (JAK2), tropomyosin receptor kinase (trk) A (TrkA), TrkB and TrkC.

        More about Lestaurtinib
        Browse All Tags